Bourla says Pfizer can maintain its dividend even in its most stretched scenarios, with dividend growth resuming after the loss-of-exclusivity period ends around 2028.
CEO Albert Bourla has said that even in the most stretched scenarios the company runs, it can maintain the dividend; he ties a return to dividend growth to the end of the loss-of-exclusivity period, which Pfizer says weighs on revenue through 2028.